Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EMP1 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
EMP1 small interfering RNA is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of Epithelial Membrane Protein 1 (EMP1). EMP1 is a four-transmembrane glycoprotein involved in cell proliferation, adhesion, and apoptosis, and its overexpression is associated with poor prognosis and drug resistance in several cancers, including non-small cell lung cancer and glioblastoma. The siRNA works by binding to and promoting the degradation of EMP1 messenger RNA (mRNA) within the RNA-induced silencing complex (RISC), thereby preventing the translation of the EMP1 protein. Research indicates that knockdown of EMP1 can inhibit tumor cell migration, invasion, and proliferation, and may restore sensitivity to EGFR tyrosine kinase inhibitors in resistant cell lines.
- Other names
- Epithelial membrane protein 1 siRNAEMP1 siRNAEMP-1 siRNAEMP 1 siRNA
02
Targets
EMP1 (Epithelial membrane protein 1)
Beyond the preview
Go deeper on EMP1 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMP1 small interfering RNA.